Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETB-DualNK-01 in Metastatic Castration-Resistant Prostate Cancer
NCT07641049Phase 1Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of ETB-DualNK-01 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Biotech Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events at 12 months and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
ETB-DualNK-01
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07641049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641049.